SEATTLE – You’ve heard of CBD, an extract derived from cannabis; the popularity and the touted benefits continue to spread.
Now a local scientist is embarking on a new clinical trial studying CBD in hopes of helping children with a rare disorder called Fragile X syndrome.
Dr. Raphael Bernier at the University of Washington is getting ready to test a CBD gel for the first time ever.
“I am a scientist so I am always cautiously optimistic,” Benier said.
Benier is hopeful that CBD will reinvigorate the brain activity in children with Fragile X.
“It’s a genetic disorder that is categorized by intellectual disability, anxiety and a number of social challenges,”Benier said.
CBD or cannabidiol is a compound found in cannabis but unlike THC in marijuana, CBD is non pyschoactive meaning it will not get the user high.
After an expected DEA approval, Dr. Bernier will start to test a CBD gel provided by Zynerba Pharmaceuticals.